International Pleuropulmonary Blastoma (PPB) Treatment and Biology Registry

NAActive, not recruitingINTERVENTIONAL
Enrollment

156

Participants

Timeline

Start Date

December 22, 2009

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2028

Conditions
Pleuropulmonary Blastoma
Interventions
DRUG

Vincristine

≥ 3 years: 1.5 mg/m2 IV x 1 (maximum dose 2 mg)

DRUG

Dactinomycin

≥ 3 years: 0.045 mg/kg (maximum dose 2.5 mg) IV X 1

DRUG

Cyclophosphamide

≥ 3 year: 1.2 gm/m2/dose IV as 1 hr infusion with IV fluids

DRUG

Ifosfamide

≥ 3 years: 3 g/m2/dose IV over 3 hours on Days 1, 2, (6 g/m2/cycle)

DRUG

Doxorubicin

≥ 3 years: 30 mg/m2/dose IV over 30 min, Days 1, 2 (60 mg/m2/cycle)

Trial Locations (1)

55404

Anne K Harris, Minneapolis

All Listed Sponsors
lead

Children's Hospitals and Clinics of Minnesota

OTHER

NCT01464606 - International Pleuropulmonary Blastoma (PPB) Treatment and Biology Registry | Biotech Hunter | Biotech Hunter